Medical insurance price of Ruxolitinib tablets

Ruxolitinib is used to treat some myeloproliferative neoplasms (MPNs), myelofibrosis and polycythemia vera. Ruxolitinib tablets belong to a group of targeted therapeutic drugs called protein kinase inhibitors, and its target genes are calledJAK1 and JAK2. These genes help control the number of blood cells the body makes. If one gene is defective, the body may make too many blood cells.

Ruxolitinib tablets block (suppress) the signal from the defective gene. This reduces the number of extra blood cells. Before treatment with ruxolitinib, blood tests are usually done to check for defective JAK1 or JAK2 genes and to block other signals that cause too many blood cells to be produced. Ruxolitinib tablets are also suitable for people who do not have JAK gene defects.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. SpecificationThe price of 5mg*60 tablets per box may be around 3,000 RMB. The reimbursement ratio and the price after reimbursement may vary in different regions. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.